Search
NanoViricides Inc
NNVCAdd to Watchlist
1.330USD
-0.050-3.62%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
28.79MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.62%
5 Days
-2.21%
1 Month
-20.83%
6 Months
+17.70%
Year to Date
+17.70%
1 Year
-5.00%
Key Figures
1.370Open
1.395High
175.25KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.81%Turnover Ratio
1.380Prev. Close
1.330Low
145.93KTurnover
LossP/E Static
3.15P/B
0.00%Div Yield TTM
-79.91%ROA
2.23052wk High
0.59Volume Ratio
-9.47MNet Profit
21.65MShares
-0.4344EPS TTM
1.66Beta
-89.97%ROE
0.85052wk Low
4.71%Amplitude
--Gross Margin
28.79MMarket Cap
-2.62Reward/Risk
5.04%Risk Rate
TradingKey Stock Score of NanoViricides Inc
Currency: USD Updated: 2026-07-01Key Insights
NanoViricides Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 193 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NanoViricides Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
NanoViricides Inc Highlights
StrengthsRisks
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
Undervalued
The company’s latest PE is -3.11, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.93M shares, increasing 34.23% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.13.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
6.000
Target Price
+334.78%
Upside Space
NanoViricides Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
NanoViricides Inc Info
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
Ticker SymbolNNVC
CompanyNanoViricides Inc
CEODiwan (Anil)
Websitehttps://www.nanoviricides.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52358.200
+103.900 (+0.20%)
29957.400
+158.100 (+0.53%)
7499.800
+24.300 (+0.33%)
14988.000
-367.000 (-2.39%)
69819.000
+334.000 (+0.48%)
6298.200
+22.800 (+0.36%)
67.661
-0.307 (-0.45%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4055.170
+24.400 (+0.60%)
FAQs
What is the current price of NanoViricides Inc (NNVC)?
The current price of NanoViricides Inc (NNVC) is 1.33.
What is the symbol of NanoViricides Inc?
The ticker symbol of NanoViricides Inc is NNVC.
What is the 52-week high of NanoViricides Inc?
The 52-week high of NanoViricides Inc is 2.23.
What is the 52-week low of NanoViricides Inc?
The 52-week low of NanoViricides Inc is 0.85.
What is the market capitalization of NanoViricides Inc?
The market capitalization of NanoViricides Inc is 28.79M.
Is NanoViricides Inc (NNVC) currently rated as Buy, Hold, or Sell?
According to analysts, NanoViricides Inc (NNVC) has an overall rating of Buy, with a price target of 6.00.
What is the Earnings Per Share (EPS TTM) of NanoViricides Inc (NNVC)?
The Earnings Per Share (EPS TTM) of NanoViricides Inc (NNVC) is -0.63.